Epilepsy Therapeutics - Pipeline Assessment and Market Forecasts to 2018

GlobalData, the industry analysis specialist, has released its new report, Epilepsy Therapeutics - Pipeline Assessment and Market Forecasts to 2018. The report is an essential source of information and analysis on the global Epilepsy Therapeutics market. The report identifies the key trends shaping and driving the global Epilepsy Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Epilepsy Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Request a Sample for or Inquire before buying the report @ http://www.reportsnreports.com/reports/135333-epilepsy-therapeutics-pipeline-assessment-and-market-forecasts-to-2018.html

Scope
The report provides information on the key drivers and challenges of the Epilepsy Therapeutics market. Its scope includes -
• Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Epilepsy Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2018.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
• Analysis of the current and future competition in the seven key countries Epilepsy Therapeutics market.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Epilepsy Therapeutics market.
• Analysis of key recent licensing and partnership agreements in Epilepsy Therapeutics market

Picture Archiving and Communications Systems (PACS)

Published: September 2011
No. of Pages: 298
Price: $ 3400

During the past 35 years, ultrasound and nuclear medicine were introduced into clinical medicine, computed tomography (CT) revolutionized diagnostic procedures and magnetic resonance imaging (MRI) emerged, bringing new diagnostic information at the cellular level. X-ray morphed from analog films to digital, and virtually all medical images became "soft" files on the electronic networks. As imaging departments in healthcare facilities have migrated from film to digital, the display and storage systems have had to migrate too. These new digital imaging storage and display systems are called picture archiving and communication systems (PACS).

Browse All: Pharmaceuticals Market Research Reports

Most PACS handle images from various medical imaging instruments, including ultrasound, MRI, positron emission tomography (PET), CT, endoscopy, mammograms, etc. The focus of this TriMark Publications report is to analyze and describe the PACS market segments. PACS market penetration in the U.S. healthcare space has been significant, at almost 90%. A PACS network typically consists of a central server that stores a database containing the images connected to one or more clients via a local area network (LAN) or a wide area network (WAN) that provides or utilizes the images. More and more PACS utilize Internet-based technologies as their means of communication. This allows remote viewing and diagnosis with implications for both civilian and military healthcare facilities. Since radiology departments dominate the production of images, interconnections with radiology information systems (RIS) are also looked at in this study.

Biomarker Technology Platforms for Cancer Diagnoses and Therapies

Published: September 2011

No. of Pages: 343

Price: $ 3400

Until superior therapeutic treatments are developed to prevent, treat and cure cancer, the best means of reducing mortality and morbidity in a disease this complex is early detection and diagnosis. In the major solid cancer types such as lung, breast, colon and prostate, long-term survival rates drop precipitously once metastatis has occurred. The case is clear for development of biomarkers for early detection and screening tests for diseases such as breast, colon, ovarian and lung cancer. In addition, diagnostic measurement of cancer disease progression is essential to successful disease management. For these reasons, development of new and effective biomarkers for cancer detection and diagnosis is central to the cancer problem. 

Browse All: Pharmaceuticals Market Research 

The use of nucleic acid biomarker diagnostics have begun to answer these questions. Protein biomarkers are also useful. The purpose of this TriMark Publications report is to describe the specific segment of the cancer diagnostics market which develops new biomarker technology platforms for diagnosing and treating cancer. Biomarkers are useful in following the course of cancer and evaluating which therapeutic regimes are most effective for a particular type of cancer, as well as determining long-term susceptibility to cancer or recurrence. This study Biomarker Technology Platforms for Cancer Diagnoses and Therapies particularly examines those clinical measurement devices, and their reagents and supplies, which are meant to be used in hospitals, clinics, commercial laboratories and doctor’s offices to diagnose and monitor cancer. The examination also provides an in-depth discussion of the application of biomarkers in developing novel targeted cancer therapeutics, their predication response and efficacy, as well as their use in diagnosis of cancer. 

European Medical Imaging Markets

Published: May 2011
No. of Pages: 110
Price: $ 3400







The European market for medical imaging equipment continues to thrive despite the impact of a global economic recession. As such, the European medical imaging market represents a dynamic and robust sector which will progressively represent an increasingly important sub-market within the medical device business. In order to provide a comprehensive and relevant analysis of the European medical imaging market, this TriMark Publications report covers the major medical imaging modalities of computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), single photon emission computed tomography (SPECT) and ultrasound. In order to reflect the ongoing shifts in the utilization of the modalities from single to multimodality systems, this study also includes analyzes of the European markets for PET/CT and SPECT/CT.

Browse All: Pharmaceutical Market Research

While the European medical imaging market is dominated by a handful of multinational players, this report surveys almost all of the companies known to be marketing, manufacturing or developing medical imaging equipment and supplies in France, Germany, Italy, Spain, the United Kingdom, the Benelux countries, Scandinavia and the rest of Europe (ROE). Each company is discussed in extensive depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company’s market position. Detailed tables and charts with sales forecasts and market data are also included. To complete the analysis of the European market, this report also reviews other factors which are instrumental in shaping the future direction of Europe's medical imaging sector. The study looks at pricing, reimbursement issues, provides an assessment of the purchasing processes for capital equipment in each target market, and reviews alternative funding methods for capital equipment purchases and the regulatory environment with its inherent issues and challenges.